BASEL, Switzerland, May 17, 2016 /PRNewswire/ --
Strekin AG, a start-up life sciences company located in Basel, Switzerland announced today the in-licensing of Pamapimod, an investigational oral inhibitor of P38 mitogen-activated protein kinase.
Strekin will build the necessary research foundation for the clinical development of Pamapimod in indications in which MAP Kinases play fundamental roles. Pamapimod has a well-established safety profile in humans. This will allow Strekin to quickly move the molecule into enabling proof-of-concept Phase 2 clinical studies in new indications, reducing the risk and time inherent in the development of less advanced candidates.
"Strekin is on a path to build a specialty pharmaceutical company focused on developing late stage drugs as disease-modifying treatments for disorders involving cell-stress related inflammatory pathways" said Alexander Bausch, CEO and Founder of Strekin.
About Strekin AG
Strekin is a privately held clinical-stage company located in Basel, Switzerland. Strekin aims to discover the untapped therapeutic potential of existing drugs for new indications to transform the lives of patients. Strekin is led by an experienced team with a strong track record in research and successful clinical development of novel drugs. Strekin's lead program, STR001, is a therapy currently in clinical development for the treatment of hearing loss. http://www.strekin.com
About Pamapimod and P38 MAPK
Pamapimod is an investigational oral drug that selectively inhibits P38 mitogen-activated protein kinase activity.
The p38 mitogen-activated protein kinases (MAPK) play central roles in cellular signaling in response to inflammation and oxidative stress. Beyond inflammation, the p38 MAPK signaling cascade is also involved in diverse biological responses including cell proliferation, differentiation, and apoptosis. Thus, Pamapimod has promise as a potential new treatment for a number of serious rare and common diseases.
Contact: Alexander Bausch, +41-61-633-2971
SOURCE Strekin AG